This website is intended for journalists outside the US/UK, who are interested in media information from Boehringer Ingelheim.

Latest Press Releases

30.09.2014

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund

27.09.2014

Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

-

For Ex-US and Ex-UK Media Only

27.09.2014

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

-

For Ex-US and Ex-UK Media Only

26.09.2014

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

-

For media outside UK and US only

18.09.2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

-

For Ex-US and Ex-UK Media Only

16.09.2014

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

-

For Non-U.S. and Non-UK Media

08.09.2014

European Respiratory Society International Congress 2014
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

-

For media outside the US, the UK and Canada

08.09.2014

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

 

-

For Media outside the US, the UK & Canada only

02.09.2014

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

-

Non-US/Non-UK/Non-Canadian Media

Top Stories

 

  •  

    Media Invite: ESMO 2014

  •  

    The Power of 140 Characters: When Social Media met the ESC Congress 2014

    Events and Initiatives

    ESMO 2014 Congress

    26th - 30th September
    Find out the latest news about Boehringer Ingelheim's treatments in oncology.

    Education Hub

     

     

    INFOGRAPHIC

    Nintedanib* Lume-Lung
    1 Clinical Trial

    INFOGRAPHIC

    Afatinib* Lux-Lung 3 & 6
    Clinical Trials

    Tweets from @Boehringer